Valuation: NeoGenomics, Inc.

Market Cap 2.48B 2.18B 2.06B 1.88B 3.51B 238B 3.54B 24.63B 9.54B 122B 9.32B 9.12B 391B P/E 2026 *
-65.2x
P/E 2027 * -77.7x
Enterprise Value 2.48B 2.18B 2.06B 1.88B 3.51B 238B 3.54B 24.63B 9.54B 122B 9.32B 9.12B 391B EV / Sales 2026 *
3.09x
EV / Sales 2027 * 2.81x
Free-Float
96.11%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 31/03/2025
Director of Finance/CFO 57 01/03/2026
President 53 31/03/2025
Director TitleAgeSince
Chairman 64 06/10/2021
Director/Board Member 63 18/07/2017
Director/Board Member 69 14/07/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%+11.69%+153.15%+817.41% 59.47B
+0.22%-3.45%+10.35%+50.78% 25.11B
-0.63%-2.34%-11.16%-38.35% 6.52B
-0.73%-6.86%-6.74%+154.37% 5.57B
-0.46%+2.92%+22.23%+61.31% 3.4B
-0.09%-12.56%-24.58%+2,376.19% 2.64B
-1.18%-2.91%+143.76%+57.03% 2.48B
+16.38%+1.68%+35.11%+45.42% 2.27B
+1.10%+4.93%+0.79%-53.43% 2B
Average +1.73%-0.64%+35.88%+385.64% 12.16B
Weighted average by Cap. +0.79%+4.90%+88.67%+521.68%

Financials

2026 *2027 *
Net sales 804M 706M 666M 607M 1.14B 77.07B 1.14B 7.97B 3.09B 39.37B 3.02B 2.95B 127B 885M 777M 733M 668M 1.25B 84.83B 1.26B 8.78B 3.4B 43.34B 3.32B 3.25B 139B
Net income -39.05M -34.27M -32.37M -29.49M -55.21M -3.74B -55.61M -387M -150M -1.91B -147M -143M -6.15B -32.73M -28.72M -27.12M -24.72M -46.27M -3.14B -46.6M -325M -126M -1.6B -123M -120M -5.15B
Net Debt - -
Logo NeoGenomics, Inc.
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA